Overweight/Obesity
Conditions
Interventions
WeChat group: At the time of enrollment, the subjects in this group will receive a routine assessment by a doctor from the community health center. The doctors, nutritionists, and nursing staff from t
Smartphone-Based Remote Intervention group:In addition to receiving the same intervention as the WeChat group, the patients in this group were also intervened with the smartphone weight management min
Sponsors
The Second Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Voluntarily to participate and sign the informed consent form; 2. Age >= 18 years old, male or female; 3, BMI >= 24 kg/m^2; 4. Able to use a device such as a computer, tablet or smartphone with unlimited Internet access; 5. Willing to lose weigh
Exclusion criteria
Exclusion criteria: 1. Secondary obesity caused by various reasons: the following thalamo-pituitary lesions, Cushing's syndrome, hypothyroidism, etc. Iatrogenic or drug-induced obesity, such as antipsychotic drugs and corticosteroids, are common 2. Obesity syndrome with definite etiology (such as PWS) 3. Women who are pregnant or breastfeeding, or who plan to become pregnant in the next 6 months 4. Alcoholics (women consume alcohol >40 g/day (2 two liquor), men consume alcohol >80 g/day) 5, severe cardio-cerebrovascular disease (such as heart failure, myocardial infarction, cerebral infarction, acute myocarditis, severe arrhythmia, receiving interventional therapy in the past 6 months) or stage III hypertension (systolic blood pressure cannot be controlled at 160 mmHg with three antihypertensive drugs) The following), severe liver and kidney function diseases (alanine aminotransferase, serum creatinine index more than 4 times the normal range set by the hospital), malignant tumor and blood disease patients who are intolerant to weight loss or have contraindications to weight loss 6, hepatitis B three positive, active tuberculosis, AIDS and other infectious diseases 7. Those with impaired physical activity ability or limited physical activity due to disease and treatment 8. Sudden weight change (>= 5kg within 3 months) without obvious reasons (such as no weight loss intervention) 9. Suffer from chronic gastrointestinal diseases that affect digestion and absorption, such as inflammatory bowel disease or celiac disease 10, patients with a history of a confirmed eating disorder and/or a self-reported history of an eating disorder, such as binge eating disorder, etc 11, taking medications that may cause weight change and being unwilling or unable to delay treatment with these medications for the duration of the trial. Drugs that may cause weight loss: orlistat, GLP-1 receptor agonists, naltrexone/bupropion, phentermine/topiramate, etc., and other weight-loss drugs. Patients were still considered eligible if they had stopped using weight-loss medications for > 1 month. Drugs that may cause weight gain: anti-schizophrenia drugs (such as chlorpromazine, etc.), antidepressants (such as amitriptyline, etc.), antiepileptic drugs (such as valproic acid, etc.), corticosteroids, antihistamines, contraceptives, insulin, etc. 12, patients on a whole fluid diet plan in the past 6 months or currently. Patients were considered to be eligible if they had returned to a normal diet after the implementation of the whole-fluid diet plan. 13, previous bariatric surgery or expected to undergo bariatric surgery during the study period 14. Have mental illness and cannot cooperate well 15, patients who plan to relocate to an area where subsequent follow-up is not available during the study period 16. Other conditions considered by the investigator to be inappropriate for enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| weight; | — |
Secondary
| Measure | Time frame |
|---|---|
| waist circumference;hip circumference;Sagittal diameter of abdomen;blood pressure;Fat content (body fat percentage, total fat content, abdominal subcutaneous fat content, visceral fat content);B-ultrasound diagnosis of fatty liver degree;Self-efficacy score;Compliance evaluation;Obesity-related knowledge score;fasting blood-glucose;Glycated hemoglobin;C-peptide;creatinine;urea nitrogen;serum uric acid;Aspartate aminotransferase;Alanine aminotransferase;Gamma-glutamyl transferase;total serum protein;serum albumin;bilirubin;C-reactive protein;triglyceride;total cholesterol;low density lipoprotein;high-density lipoprotein; | — |
Countries
China
Contacts
Public ContactHoude Zhou
The Second Xiangya Hospital of Central South University
Outcome results
None listed